Structure-Function Correlation Using a Targeted Image- Guided Microperimetry Approach for Retinal Atrophic Diseases: A Methods Study
Preprint
Abstract
Purpose This proof-of-concept aimed to evaluate the feasibility of targeted, image-guided microperimetry (IGMP) by integrating Optical Coherence Tomography (OCT) and Fundus Autofluorescence (FAF) for lesion mapping and functional assessment in retinal atrophic diseases. Methods 22 eyes were identified, of which 17 had early geographic atrophy (GA) while 5 had Stargardt Disease (SD). Disease transition zones (TZs) on OCT and FAF were annotated onto enface infrared images. These were then exported with microperimetry assessments to custom MATLAB applications. IGMP patterns were thereafter created and imported using MAIA and Nidek microperimeters for subsequent scans. Mean procedure and examination times (mins), retinal sensitivity (dB), approach feasibility, and algorithm compatibility of targeted IGMP were reported as outcomes. Results Targeted IGMP was quicker than the standard 10-2 grid for both SD and GA lesion assessments. SD cases showed longer mean procedure and examination times and lower mean retinal sensitivity in all zones compared to GA lesions. Targeted IGMP procedure was lengthier for Nidek (29.2±7.1 mins) than MAIA (17.4±4.3 mins) although examination took longer on MAIA (4.0±1.0 mins) than on Nidek (3.6±1.2 mins). Overall, IGMP approach is feasible (100.0%) and the algorithm is compatible (100.0%) on both MP devices for all subjects tested. Conclusions This study establishes the feasibility of an IGMP workflow in providing targeted functional assessments in retinal degenerative diseases. Our approach may help enhance structure- function correlation and optimize the efficiency of microperimetry integration for clinical trials. Further validation in larger cohorts is needed to assess its broader clinical applicability.Keywords
This publication has 36 references indexed in Scilit:
- Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks TrialAmerican Journal of Ophthalmology, 2025
- Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month ResultsAmerican Journal of Ophthalmology, 2019
- Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta ExperienceAmerican Journal of Ophthalmology, 2018
- Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular DegenerationJAMA Ophthalmology, 2018
- Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo StudyAmerican Journal of Ophthalmology, 2018
- Evaluating the Usefulness of MP-3 Microperimetry in Glaucoma PatientsAmerican Journal of Ophthalmology, 2018
- Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9)JAMA Ophthalmology, 2017
- Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) StudyJAMA Ophthalmology, 2017
- Visual Function in GlaucomaOphthalmology, 2011
- SURF: Speeded Up Robust Features2006